Beijing Hanmi Pharmaceutical Co., Ltd.

Maengsup Kim

Jiawang Liu

Nanmeng Song

Yaping Yang

Mi Young Cha

Gong Li

Wenchu Xiao

Jinming Liu

Zhanmei Li

Hongjuan Qiu

Wei Zhang

Bo Zhang

Tao Ma

Yuhua Li

Lina Zhang

Tao Zhao

Zhenlei Li

Hai Xue

Dongge Yang

Hai Yang

Chulwoong Chung

Chunguang Zhan

Mingyue Gu

Sunghwan Moon

Qinguan Cai

Ning Shen

Zhijun Liu

Shusen Xu

Jiangcheng Xu

Runa Zheng

Baoyu Xue

Qingyuan Cai

Provided are an anti-TNFα/anti IL-17A natural antibody structure-like heterodimer form of a bispecific antibody and a preparation method therefor, wherein the antibody can bind two target molecules simultaneously, and can be used for treating complex diseases.

Anti-TNFα/anti IL-17A natural antibody structure-like heterodimer form of bispecific antibody and preparation method therefor

An anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof. Provided are a highly stable, heterodimeric form anti-PD-1/anti-VEGF bispecific antibody having natural IgG characteristics and free of mismatched heavy and light chains and preparation method for the antibody. The bispecific antibody is capable of simultaneously binding with two target molecules and provides improved efficacy in treating a complicated disease.

Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof

Provided are an anti-PD-L1/anti-CD47 bispecific antibody that has natural IgG characteristics and is in a highly stable heterodimer form without the heavy chain and light chain being mismatched, and a preparation method therefor. Either the first Fc chain or second Fc chain of the bispecific antibody comprises amino acid substitutions at positions 366 and 399, and the other comprises amino acid substitutions at positions 351, 407 and 409.

Anti-PD-L1/anti-CD47 bispecific antibody

The present invention provides a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., bispecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can simultaneously bind two target molecules and are more potent in the treatment of complex diseases.

Heterodimeric immunoglobulin constructs and preparation methods thereof

Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. Specifically, provided are a highly stable anti-PD-1/anti-HER2 heterodimeric bispecific antibody having characteristics of a natural IgG and having no mismatched heavy chain and light chain, and a method of preparing the same. The bispecific antibody may bind to both of two kinds of target molecules, and thus may be more effective in treating complex diseases.

Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same

The present invention relates to a compound inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (particularly humans). The compound has a structural formula I. 

IRAK4 inhibitor and use thereof

Disclosed are a compound related to inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (especially humans). The compound has a structural formula I. 

Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a ROR&#x3b3; mediated disease. The compound has the structural formula (I). 

N-benzoate group substituted benzopyrroline-2-one derivative and use thereof

The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I). 

Compound inhibiting activities of BTK and/or JAK3 kinases

The present invention provides a GIP analog, which is derived from GIP (1-29, SEQ ID NO: 1), has both GLP-1 agonist activity and GIPR stimulation activity, and comprises an amino acid sequence represented by the following formula I: Tyr-A2-A3-Gly-Thr-Phe-A7-Ser-Asp-Tyr-Ser-A12-A13-A14-A15-Lys-A17-A18-A19-A20-A21-A22-A23-A24-Trp-Leu- A27-A28-A29-Y. The present invention also provides a pharmaceutical composition comprising the GIP analog and use thereof.

Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof

Growing community of inventors

Beijing, China

Maengsup Kim